B7-1 (CD80) and B7-2 (CD86) are genetically and structurally related molecules expressed on antigen-presenting cells. Both bind CD28 to co-stimulate T lymphocytes, resulting in proliferation and cytokine production. The extracellular portions of B7-1 and B7-2 which bind to CD28 and CTLA-4 are related to Ig variable (V) and Ig constant (C) domain sequences. Recent reports have described splice variant forms of B7 proteins which occur in vivo and are of unknown function. Here we describe soluble recombinant forms of B7-1 and B7-2 containing either both of the Ig-like extracellular domains or the individual IgV or IgC domains coupled to an Ig Fc tail. Soluble B7-1 and B7-2 bind to CD28 and CTLA-4, and effectively co-stimulate T lymphocytes resulting in their proliferation and the secretion of cytokines. Furthermore, the IgV domain of B7-2 binds CD28 and CTLA-4, competes with B7-1 and B7-2 for binding to these receptors, and co-stimulates T lymphocytes. Cross-linked soluble B7-2v was the most potent co-stimulatory molecule tested and was active at a concentration~100-fold lower than cross-linked soluble B7-1 or B7-2 proteins. When bound to tosyl-activated beads, B7-2v was capable of sustaining multiple rounds of T cell expansion. These data complement the description of naturally occuring variants to suggest that T cell co-stimulation in vivo may be regulated by soluble or truncated forms of B7 proteins.
Introduction
The requirement for a co-stimulatory signal in T cell activation structurally and functionally similar, nonetheless it is possible that they have distinct roles in the regulation of an immune is well known (1, 2) and the function of CD28 in transducing this signal has been demonstrated (3) . Engagement of CD28 on response (12) (13) (14) (15) (16) . B7-1 and B7-2 are also ligands for the T cell activation antigen CTLA-4 (17,18) whose function can be downthe T lymphocyte surface is required for IL-2 up-regulation leading to a sustained immune response (4) . Blockage of the regulatory (19,20) or co-stimulatory (21) . Analyses of B7-1 and B7-2 function have used antigen-presenting cells or transfec-CD28 signal concurrent with the delivery of the primary activation signal leads to a T lymphocyte unresponsive state termed tants to present the co-stimulatory signal to T cells. Although blocking mAb used in these studies demonstrate specificity, anergy (5) or to cell death (6) . The B lymphocyte activation antigens B7-1 [CD80 (7) ] and B7-2 [CD86 (8, 9) ] are related they do not formally rule out effects of other cell surface molecules or secreted factors. This may be particularly relevant in membrane bound proteins expressed by antigen-presenting cells. Both are ligands for CD28 and can deliver a co-stimulaanalyses of T cell cytokine profiles resulting from co-stimulation. The possible expression of variant forms of B7-1 and B7-2 in tory signal to T lymphocytes via the CD28 pathway (9) (10) (11) . Most reports have shown that B7-1 and B7-2 are genetically, vivo could further complicate the study of T cell activation.
In this study, we have used domain-specific constructs of dimers. The remainder of the proteins existed primarily as higher order multimers with a small amount of monomer also human B7-1 and B7-2 and tested the ability of these constructs to bind to CD28 and CTLA-4 and to co-stimulate T cells. We present. CTLA-4-Ig existed predominately as a covalently linked dimer with higher order multimers also present. Protein demonstrate that soluble B7-1, B7-2 and the IgV-like domain of B7-2 bind CTLA-4 and CD28. In contrast, the B7-1 IgV and concentration was determined by spectroscopy. Endotoxin levels were determined by ELISA (BioWhittaker, Walkersville, IgC domains and the B7-2 IgC domain were unable to bind CD28 or CTLA-4. Importantly we provide the first demonstra-MD) for all preparations and were Ͻ5 EU/mg purified protein. tion that soluble B7-2 V domain proteins can co-stimulate T mAb lymphocytes leading to proliferation and the production of cytokines. Our results indicate that B7-1 and B7-2 have mAb to human B7-1 and B7-2 were prepared using SP2/0 cells and standard protocols (27) . Briefly, BALB/c female different structural requirements for binding to CD28 and CTLA-4, in agreement with recent reports (22, 23) . Differential mice (Taconic, Germantown, NY) were immunized i.p. with either 50 µg B7-2Ig emulsified in complete Freund's adjuvant expression of membrane bound or soluble full length and domain-specific forms of B7-2 could have independent and (Sigma, St Louis, MO), 10 6 CHO/B7-2 cells (14) or 10 6 CHO/B7-1 cells (14) and boosted twice at 14 day intervals. distinct effects on the generation of immune responses.
Hybridoma colonies were established in 96-well tissue culture plates and the culture supernatants were assayed by ELISA Methods for direct binding to either B7-1Ig or B7-2Ig. All mAb were purified from ascites fluid on Protein A-Sepharose as Cloning, expression and purification of reagents described above. mAb B70 was purchased from PharMingen (San Diego, CA). Anti-CD3 mAb OKT3 was prepared from PCR was used to create extracellular and domain specific gene expression constructs using B7-1 and B7-2 cDNAs as ascites using hybridoma CRL8001 (ATCC, Rockville, MD). Purified mAb were tested for their ability to bind to the templates for the coding regions. All expression constructs were composed of a signal sequence coupled to the respectvarious B7Ig forms as follows. Maxisorp plates were coated overnight at room temperature with 20 µg/ml of purified B7Ig ive B7 domain(s) coupled to the human IgG1 modified hinge-C H 2-C H 3 sequences as previously described (14). The protein in PBS. The plates were then blocked with PBS/1% BSA for 1 h. Purified antibody (5 µg/ml in PBS) was added boundaries of the IgV and IgC domains were selected to correspond to the genomic structure of the human B7-1 and to the test wells, the plates incubated for 1 h and then washed five times with PBS/0.05% Tween 20. Goat anti-mouse IgG-B7-2 genes (24,25), and to the predicted N-termini (7, 9) . Briefly, the full length B7-1 extracellular domain extended horseradish peroxidase (HRP) (1:1000 dilution in PBS; Zymed, San Francisco, CA) was added for 1 h. The plates were from predicted amino acid 1 (glycine) to amino acid 215 (aspartic acid). The IgV domain of B7-1 extended from amino washed five times and developed using ABTS (Zymed).
Absorbance was read at 405 nm. Anti-B7 mAb were scored acid 1 (glycine) to 115 (aspartic acid). The IgC domain of B7-1 extended from amino acid 114 (alanine) to 215 (aspartic as having positive (ϩ) reactivity for the various B7Ig proteins when absorbance values were Ͼ1.5 and negative (-) reactivity acid). The B7-2 extracellular domain extended from amino acid 23 (alanine) to 237 (glutamic acid). The B7-2 IgV domain for values Ͻ0.2. None of the mAb reported here exhibited an intermediate level of reactivity. extended from amino acid 23 (alanine) to 133 (leucine). The B7-2 IgC domain extended form amino acid 134 (alanine) to CTLA-4 binding assays 237 (glutamic acid). All PCR primers were designed such that the final reaction products were bounded on the 5Ј end Maxisorp plates were coated overnight at room temperature with 50 µl/well of a 20 µg/ml stock of the various B7Ig proteins by a unique HindIII restriction site and on the 3Ј end by a unique BclI restriction site to facilitate insertion into the or purified human IgG (Zymed) in PBS. The plates were blocked with PBS/1% BSA for 1 h then incubated with varying expression vector.
The final gene expression constructs were prepared by amounts of biotinylated CTLA-4-Ig for 2 h at room temperature. After five washes with PBS, streptavidin-HRP (Zymed, 1:1000 ligating the HindIII-BclI digested PCR fragments into the expression vector pNRDSH-Ig. This vector featured a CMV dilution) was added for 20 min. The plates were washed with PBS and the HRP reactivity was measured as described promoter, HindIII and BclI restriction sites for insertion of the B7 segment, a human hinge, C H 2 and C H 3 domains from IgG1, above.
The ability of the various B7Ig forms to bind to CTLA-4-Ig and a polyadenylation signal. All cysteines were replaced by serines in the IgG1 hinge region (14).
was also analyzed in a competition format. Maxisorp plates were coated and blocked as described for the direct ELISA All recombinant proteins were prepared by transient expression in COS-7 cells using standard techniques (26). Culture assay, using B7-1Ig or B7-2Ig. Biotinylated CTLA-4-Ig was added at 35 ng/ml, a concentration determined to be onemedium containing the various B7Ig proteins was harvested at 72 h post-transfection. The various B7Ig proteins were half saturation in the direct binding curve for B7-1. Purified protein of the various forms of B7Ig was added in varying purified by affinity chromatography on Protein A-Sepharose (Repligen, Cambridge, MA). The amount of protein expressed amounts and the plate was incubated for 2 h at room temperature. The plates were incubated with streptavidinper milliliter of transfection media varied, but in all cases highpurity protein (Ͼ90%) of the expected mol. wt was prepared HRP, washed and developed as described above. The ability of the anti-B7-2 mAb to inhibit the binding of as measured by SDS-PAGE gels. B7Ig recombinant protein preparations were predominantly non-covalently linked CTLA-4-Ig to B7-2 was tested using a competition ELISA format. The mAb (5 µg/ml) were mixed with 35 ng/ml biotinyltion was reduced to Ͻ10% of the uninhibited control value or negative (-) when the amount of [ 3 H]-thymidine incorporation ated CTLA-4-Ig (NHS-LC-biotin; Pierce, Rockford, IL) and then added to microtiter plates coated with B7-2-Ig. After 1 remained the same as the uninhibited control value. h the plates were washed five times with PBS/0.05% Tween Long-term cell culture 20. Streptavidin-HRP (Zymed; at a 1:1000 dilution in PBS)
Peripheral blood lymphocytes were isolated by Percoll gradiwas added for 1 h then washed, developed and read as ent centrifugation from leukopacks obtained by apheresis of described above. The ability of mAb to inhibit the binding of healthy donors. CD28 ϩ CD4 ϩ T cells were purified by a CTLA-4-Ig to B7-2 was scored as positive (ϩ) when the previously described negative selection method (28) . In each absorbance value was reduced to Ͻ0.2 and as negative (-) experiment the purity of the cell preparations was monitored when the absorbance value was within 10% of the uninhibited by flow cytometry: the cells from such preparations were control (absorbance~1.5). None of the mAb reported here Ͼ99% CD2 ϩ , Ͼ98% CD3 ϩ , Ͼ98% CD28 ϩ and contained exhibited an intermediate level of reactivity.
Ͻ3% CD8 ϩ cells.
FACS analysis
Dynal M450 tosyl activated beads (Dynal, Great Neck, NY) were coated with mAb or recombinant proteins according The ability of soluble forms of B7Ig to bind to CD28 was to the manufacturer's instructions. Beads were coated with tested by FACS (FACScan; Becton Dickinson, San Jose, CA)
anti-CD3 (OKT3) alone or approximately equimolar ratios of using Jurkat cell lines E6.1 (CD28 ϩ /CTLA-4 -) and RT3 (CD28 -/ anti-CD3 and anti-CD28 mAb 9.3 or the B7Ig proteins. Proteins CTLA-4 -), CHO and CHO/CD28. The flow cytometer was were prepared in borate buffer (pH 9.5) at 75 µg/ml prior to calibrated using CaliBRITE beads and AutoComp software coupling to the beads. (Becton Dickinson). All data aquisition and analysis was Purified CD4 ϩ T cells were cultured at 1ϫ10 6 cells/ml in performed using the Lysys II programs (Becton Dickinson).
R10 complete medium (Gibco/BRL, Gaithersburg MD). T cells Three micrograms of various B7Ig proteins were cross-linked were stimulated with anti-CD3-coated beads, anti-CD3 plus by incubation with 10 µg of affinity-purified FITC-labeled goat anti-CD28-coated beads or anti-CD3 plus B7Ig protein-coated anti-human IgG Fc (Cappel, Durham, NC) for 30 min on ice.
beads. The coated beads were initially added at a ratio of 3 The cross-linked B7Ig proteins were added to 10 6 Jurkat or beads/cell. The cell cultures were fed at 2-3 day intervals CHO cells previously washed and suspended in 100 µl cold with fresh medium to maintain cell concentrations between HBSS (BioWhittaker). The cells were washed twice with cold 0.5 and 1.5ϫ10 6 T cells/ml; antibody-coated beads were HBSS, suspended with 250 µl cold HBSS and fixed using diluted progressively until re-stimulation. Exogenous cytokines 250 µl of 2% paraformaldehyde in HBSS. In mAb blocking or feeder cells were not added to the cultures. experiments, anti-B7-2 mAb were added at 30 µg/ml in conjunction with the B7-2Ig protein. Inhibition of B7-2Ig protein binding to CD28 ϩ cells was scored as positive (ϩ) when the Results FACS signal was reduced to that seen with the secondary Antibodies to the B7-2 V domain block B7-2 function FITC-labeled mAb alone or negative (-) when no change in signal was seen from the uninhibited controls.
In order to study the functional capacity of the B7-1 and B7-2 extracellular domains, fusion proteins consisting of the T cell proliferation assays individual IgV and IgC domains coupled to the IgG1 Fc region CD28 ϩ T cells were isolated from normal human volunteers were prepared (Fig. 1) . In ELISA analyses anti-B7-2 mAb as described (28) . T lymphocytes were used at 1.2ϫ10 5 /well recognized the entire extracellular regions and either the IgV in 96-well format. T cell proliferation was induced using antior IgC domains of B7-2 ( Table 1 ). All of the anti-B7-2 mAb CD3 (OKT3; coated on plates at 10 µg/ml overnight) or tested specifically bound to CHO/B7-2 cells and to activated phorbol myristate acetate (PMA; 1 ng/ml) to deliver a primary human B cells (data not shown) in FACS analyses. The mAb signal and anti-CD28 [10 µg/ml; mAb 3D10 (14)], CHO/B7-1 did not recognize B7-2 proteins in Western blot assays cells (5ϫ10 4 cells/well), CHO/B7-2 cells (5ϫ10 4 cells/well) or following SDS-PAGE demonstrating that denaturation of the purified B7Ig proteins to deliver the co-stimulatory signal.
protein destroyed the epitopes recognized by the antibodies. CHO cells were pretreated with mitomycin C (Sigma) overnight None of the anti-B7-2 mAb showed any cross-reactivity with and extensively washed prior to use. Purified Ig-tailed proteins B7-1 nor did anti-B7-1 mAb recognize B7-2 (data not shown). were pre-incubated with a 3-fold excess (w/w) of affinityCompetition assays showed that mAb to B7-2 could be purified goat anti-human IgG Fc (Cappel) for 30 min on ice divided into two groups on the basis of their ability to interrupt prior to use. After 60 h incubation, the cells were pulsed B7-2 binding to CD28 and CTLA-4 and inhibit T cell coovernight with [ 3 H]thymidine (Dupont/NEN, Boston, MA) and stimulation (Table 1) . Anti-B7-2v, but not anti-B7-2c mAb then harvested for counting. [ 3 H]Thymidine incorporation was blocked binding of the B7-2vIg fusion protein to CD28 and calculated from triplicate points and the results shown are CTLA-4, in FACS and ELISA assays respectively. Furthermore, representative of at least three separate experiments. Cytokine anti-B7-2v but not anti-B7-2c domain-specific mAb blocked levels were determined in duplicate by ELISA (Endogen, B7-2-mediated co-stimulation in T cell proliferation assays Cambridge, MA) using cell culture supernatants harvested (Table 1) . after 18 and 120 h of co-stimulation. When tested as compet-
The variable domain of B7-2 binds to CD28 and CTLA-4 itors of co-stimulation, anti-B7-2 mAb were added at 20 µg/ ml final concentration. Co-stimulation inhibition was scored Since the mAb blocking experiments suggested that only the IgV domain of B7-2 was required for binding, soluble as positive (ϩ) when the amount of [ 3 H]thymidine incorpora- 
a mAb binding to B7-2Ig, B7-2vIg or B7-2cIg was determined by reacting the various mAb with the recombinant B7Ig proteins previously coated on microtiter plates. Bound mAb were detected using HRP-labeled goat anti-mouse IgG and ABTS. Antibody recognition of recombinant proteins was scored (ϩ) for absorbance values Ͼ1. any reactivity with CTLA-4 (Fig. 2) . The B7Ig forms were also tested for their ability to compete with either B7-1Ig or B7-2Ig recombinant forms of B7-1Ig, B7-2Ig, and the individual IgV and IgC domains were tested for binding to CD28 and CTLAfor binding to CTLA-4. B7-1Ig, B7-2Ig and B7-2vIg competed with B7-2Ig for binding to CTLA-4 and exhibited IC 50 values 4. In direct binding experiments with CTLA-4, the recombinant proteins containing the entire extracellular domains of B7-1 of 1, 16 and 35 nM respectively. B7-2cIg, B7-1vIg and B7-1cIg were not able to compete with the binding of B7-2Ig and B7-2 or the V domain of B7-2 (B7-2vIg) bound to CTLA-4. In this assay format, half-saturation occurred at 1 nM for for CTLA-4. Similarly, B7-1Ig, but not B7-1vIg or B7-1cIg, competed with B7-1Ig for binding to CTLA-4. Thus B7-2vIg B7-1Ig, 5 nM for B7-2Ig and 8 nM for B7-2vIg. Neither subfragment of B7-1 (B7-1vIg or B7-1cIg) nor B7-2cIg showed was the only one of the IgV or IgC domain-specific proteins which bound CTLA-4 and competed with full length B7-1 and B7-2 for their binding to CTLA-4. Binding of the various B7Ig forms to CD28 was tested by The V domain of B7-2 co-stimulates T lymphocytes FACS, as described in Methods. Purified B7Ig proteins were B7Ig proteins were cross-linked using affinity-purified goat first reacted with FITC-conjugated goat anti-human IgG Fc anti-human IgG Fc and added to CD28 ϩ T lymphocytes in and then applied to CD28 ϩ Jurkat cells (E6.1), CD28 -Jurkat the presence of PMA. T cell proliferation was measured cells (RT3), CHO cells expressing CD28 or CHO cells alone. after 3 days. Cross-linked B7-1Ig protein delivered a weak B7-1Ig, B7-2Ig and B7-2vIg all bound specifically to the proliferative co-stimulus similar to previous results from Damle CD28 ϩ E6.1 cells and to the CHO/CD28 ϩ cells, but failed to and coworkers (29). Cross-linked B7-2Ig protein also bind to the CD28 -RT3 cells or untransfected CHO cells (Fig. delivered a weak co-stimulatory signal to PMA-activated T 3 and data not shown). Cross-linked B7-1Ig and B7-2Ig bound lymphocytes, whereas an equivalent amount of cross-linked heterogenously to both E6.1 and CHO/CD28 ϩ cells, perhaps B7-2vIg provided a much stronger signal that was similar in reflecting different degrees of multimerization upon crossstrength to that provided by CHO cells expressing B7-1 or linking. B7-2vIg bound E6.1 and CHO/CD28 ϩ cells in a single B7-2 on their surface (Fig. 4) . Cross-linked isotype-matched distinct peak. Control Ig protein, B7-2cIg, B7-1vIg and B7-control Ig protein failed to induce proliferation in this assay, 1cIg did not show specific binding to any of the cell lines as did cross-linked B7-2cIg, B7-1vIg or B7-1cIg (Fig. 4 and tested. The binding B7-2Ig and B7-2vIg to the CD28 ϩ Jurkat data not shown). Blocking experiments with anti-B7-2 mAb cells was blocked by all of the mAb which blocked the binding again demonstrated that mAb specific for the V domain of of B7-2Ig or B7-2vIg to CTLA-4 ( Table 1 ). The addition of B7-2 could block co-stimulation, while those specific for the CTLA-4-Ig or an anti-CD28 mAb also effectively blocked C domain could not ( Table 1) . binding of B7-1Ig, B7-2Ig and B7-2vIg to CD28-expressing Titrated amounts of B7-1Ig, B7-2Ig or B7-2vIg were added cells (data not shown).
to T lymphocytes in the presence of immobilized anti-CD3, Surprisingly, the fluorescent signal observed with crossand the accumulation of IL-2 (18 h) and cell proliferation were linked B7-2vIg was reproducibly stronger than that seen for measured (72 h; Fig. 5 ). Cross-linked B7-1 or B7-2 effectively cross-linked B7-2Ig and was comparable to that determined co-stimulated CD28 ϩ T lymphocytes resulting in their proliferafor anti-CD28 mAb (Fig. 3) . The increased FACS signal seen tion and the production of IL-2 in a dose-dependent manner. was not due to molar differences in concentration of the The proliferative response rapidly decreased with decreasing proteins as determined by titration analyses (data not shown).
B7-1Ig or B7-2Ig and was only slightly above control levels Also, the binding of B7-2vIg to CD28 ϩ CHO transfectants in when present at 1 µg/ml. In contrast, B7-2vIg was much more an ELISA format assay using serial dilutions of B7Ig proteins effective as a co-stimulatory molecule, driving appreciable also showed that cross-linked B7-2vIg was a stronger ligand for CD28 than B7-2Ig or B7-1Ig (data not shown).
proliferation and IL-2 production at levels of only 0.01 µg/ml. of anti-CD3 plus anti-CD28, or B7-1Ig, B7-2Ig or B7-2vIg immobilized on Dynal beads and the total cell numbers monitored over a period of 12 days. Cells stimulated with anti-CD3 alone failed to proliferate and the culture was terminated on day 10. All determinations were Table 2 . Production of cytokines after co-stimulation by B7- Table 2 and data not shown). B7-1Ig  734  0  10  6  28  10  B7-2Ig  1557  1040  11  19  43  12 B7-2vIg drives multiple cycles of T cell proliferation B7-2vIg  3073  2620  30  41  38  30 We have recently shown that CHO cells expressing either B7-a CD28 ϩ T lymphocytes were incubated with anti-CD3 and either 1 or B7-2 can mediate long-term autocrine proliferation of B7-1Ig (10 µg/ml), B7-2Ig (10 µg/ml) or B7-2vIg (3 µg/ml) and the accumulation of individual cytokines measured by quantitative ELISA CD4 ϩ T lymphocytes in conjunction with anti-CD3 stimulation in the culture medium after 18 and 120 h. (28) . To further test the function of the various B7 fusion proteins, CD4 ϩ T cells were cultured with beads coated with anti-CD3 mAb plus anti-CD28 mAb, B7-1Ig, B7-2Ig or B7-2vIg and the total number of cells monitored (Fig. 6 ). T cells Half maximal concentration was~0.03 µg/ml for B7-2vIg and stimulated with anti-CD3 alone failed to proliferate while those 3 µg/ml for B7-2Ig, an~100-fold difference.
stimulated with anti-CD3 plus B7-1Ig went through two cycles CD28 ϩ T lymphocytes were cultured in the presence of of replication and then underwent apoptosis as evidenced by immobilized anti-CD3 and cross-linked B7-1Ig (10 µg/ml), B7-the fragmentation of their DNA on day 5 (data not shown). It 2Ig (10 µg/ml) or B7-2vIg (3 µg/ml) and the culture medium seems likely that the signal induced by cross-linked B7-1Ig assayed for the presence of IL-2, IL-4, IFN-γ and granulocyte did not generate sufficient IL-2 to allow T cell survival. In macrophage colony stimulating factor (GM-CSF) at 18 or 120 contrast, co-stimulation by anti-CD3 plus anti-CD28, B7-2Ig h ( Table 2) . Anti-CD3 alone induced the production and or B7-2vIg drove T lymphocytes through multiple rounds of secretion of small amounts of IL-2, IL-4 and IFN-γ after 18 h.
replication with the total number of cells increasing 20-fold All three co-stimuli induced moderate levels of IL-4, IFN-γ and over a 10 day period (Fig. 6) . Continued stimulation by anti-GM-CSF, and high levels of IL-2 after 18 h. B7-2vIg co-CD3 plus anti-CD28, B7-2Ig or B7-2vIg resulted in an identical, stimulation led to production of the highest levels of all continued logarithmic increases in cell numbers over a 30 the cytokines tested. After 120 h, B7-2Ig and B7-2vIg coday period (data not shown) indicating that the IgV domain stimulation resulted in sustained, high-level expression of ILof B7-2 alone can provide a co-stimulatory signal as effective 2 and IL-4 as compared to cultures receiving B7-1Ig costimulation or in those receiving only the anti-CD3 signal.
as anti-CD28 mAb or full length B7-2Ig.
Discussion
or anti-CD3 mAb induced significant T cell proliferation and accumulation of IL-2 that was several fold greater than that Although they share only a moderate level of homology, seen with either B7-1 or B7-2. Also, the proliferative activity the B7-1 and B7-2 molecules recognize the same ligands of B7-2vIg persisted down to 10 ng/ml (250 pM B7-2vIg) and co-stimulate T cell proliferation through the CD28 when using anti-CD3 to provide the first signal; neither B7-1 receptor pathway (8) (9) (10) (11) . Although differences in the pattern nor B7-2 were co-stimulatory at 1 µg/ml. Co-stimulation with of expression of B7-1 and B7-2 on antigen-presenting cross-linked B7-1Ig, B7-2Ig or B7-2vIg induced IL-2, IFN-γ cells have been described, analyses of the functional and IL-4 at levels that reflected the amount of proliferation, consequences of CD28 receptor engagement by B7-1 and rather than a fundamental difference in the array of cytokines B7-2 have yielded disparate results (12) (13) (14) (15) (16) 28, 30) . In produced. Multiple rounds of co-stimulation with B7-2 can addition, splice variants of B7 proteins which yield domaindrive T cells toward a T h 2 cytokine profile as has been shown specific forms have been described and a possible soluble using antigen specific antigen-presenting cells and with transform has been identified (31) (32) (33) (34) . The function of these fectants (14,30). We have not yet determined if multiple rounds proteins is largely unknown. In an effort to determine the of co-stimulation using soluble B7-2Ig or B7-2vIg will have a functionality of soluble B7 proteins in general, and V or C similar effect. Multiple rounds of co-stimulation do result in domains in particular, we constructed individual IgV and the significant expansion of T cell populations, as shown IgC domains of B7-1 and B7-2 as IgG Fc fusion proteins in the studies using protein-coated tosyl-activated beads. and determined whether they retained activity.
Curiously, B7-1-coated beads were unable to sustain T cell Our results show that soluble B7-1Ig and B7-2Ig proteins expansion beyond two rounds of co-stimulation. Since the retain all of the binding and co-stimulatory activities of the cells died by apoptosis in these experiments we hypothesize membrane bound proteins. Furthermore the V domain of that insufficient IL-2 was being produced to maintain the B7-2 retains all of the binding and co-stimulatory functions viability of the activated cells. of the full length protein. Soluble B7-1Ig, B7-2Ig and B7-Several attempts have been made to identify the ligand 2vIg bound soluble CTLA-4-Ig in ELISA format at 1, 5 binding sites on B7-1 and B7-2, and on CD28 and CTLA-4, and 8 nM respectively in fair agreement with affinity using sequence homology data, hybrid CD28/CTLA-4 proteins measurements using soluble B7 proteins or CHO/B7 transand mutational analysis (22,23,35-37). These studies defined fectants (23, 35) . Competition studies showed that B7-2vIg regions of CD28 and CTLA-4 required for binding to B7-1 competed for binding to CTLA-4 as well as B7-2Ig. Thus and B7-2 within the highly conserved CDR3-like domain and we conclude that all of the sequences required for the in the CDR-1 like region (22,23). Replacement of one amino binding of B7-2 to CTLA-4 are contained within the V acid in the CDR3 region of CTLA-4 eliminated binding to B7-domain. We have refrained from labeling the interactions 2 but only partially diminished binding to B7-1 (35) , indicating of the soluble proteins with CTLA-4 as affinities since the differential binding sites. Mutational analysis of B7-1 and B7-purified proteins contained a mixture of multimeric forms 2 suggested that conserved residues within the V domains with potentially different binding capacities. Soluble B7-1Ig, of these proteins were critical for binding to CTLA-4 and B7-2Ig and B7-2vIg also bound to CD28-expressing cells CD28 (36, 37) . Moreover the latter study demonstrated that in FACS analyses. Surprisingly the FACS signal obtained neither IgV nor IgC domain-specific B7-1 fusion proteins were using B7-2vIg was significantly brighter than that of the full capable of interacting with CTLA-4 and CD28, in agreement length proteins and could not be accounted for by the with results presented here. small increase in molar concentration of the B7-2vIg form.
Membrane-bound splice variants of murine B7-1 have been It is possible that the CD28 binding site is more accessible described (31, 32) . While the C domain form is inactive (31), on the B7-2vIg protein than in the full length forms or that the V domain form appears to have binding and functional the B7-2 C domain contains a down-regulatory function.
activity. When expressed on the surface of transfectants this Alternatively the B7-2vIg protein may cross-link more readily variant induced the proliferation of activated, but not resting, than either B7-1Ig or B7-2Ig. We have not characterized T cells (32) . Other transmembrane-containing splice variants the binding of the various B7 proteins to CD28 as affinity, of murine B7-2 have been described (33) but their functional since by cross-linking these proteins with anti-human IgG capacity is not yet known. Soluble forms of B7-1 or B7-2 have antisera prior to presenting them to CD28 ϩ cells we have not been described in either mouse or human, and all known presumably added a significant avidity effect. The difference splice variants retain the transmembrane domain at the mRNA in CD28 binding seen in the FACS experiments could be level. Recently, a soluble CD28-dependent co-stimulatory readily explained by different avidities produced by greater activity produced by B7-2-positive porcine endothelial cells or lesser cross-linking of the Ig fusion proteins. An was described (34) . The authors speculated that this coexplanation for the B7-2vIg molecule's increased binding stimulatory activity was derived from a soluble form of B7-activity will require thorough biochemical characterization.
2. Thus there may be precedence for soluble forms in Nonetheless, the ability of B7-2vIg to compete with B7-2Ig other species. for binding to CD28 ϩ cells indicates that all of the sequences We show here that the soluble forms of B7-1Ig, B7-2Ig and required for binding to CD28 are contained within the V B7-2vIg become effective co-stimulators of T lymphocytes domain of B7-2.
when cross-linked using an anti-IgFc antiserum or attached The greatly increased co-stimulatory activity of B7-2vIg to beads, and that B7-2vIg stimulus can be as strong as that shows that the increased binding to CD28 has a functional provided by cell surface expressed B7-1 or B7-2. These studies demonstrate that human B7-1, B7-2 and B7-2v proconsequence. Cross-linked B7-2vIg added with either PMA 
